News
/news
asabys.comCrawled Oct 15, 2026
Anna Bellmunt joined Asabys in 2021 as a senior associate, sourcing and assessing opportunities across scientific, development and business dimensions. She is a board observer at Ona Therapeutics and Nuage Therapeutics and previously was an Investment Analyst at LSP.
Antonio Limatola joined Asabys in 2022 as a senior associate, evaluating opportunities across biotech and HealthTech therapeutic areas. He is a board observer at Inbrain Neuroelectronics, SafeHeal and ALLOX and previously worked as an Investment Analyst at Inkef Capital.
Joana Correia joined Asabys in 2025 through the Aliath-Asabys integration after sourcing and assessing biotech investment opportunities at Aliath Bioventures. She was an Investment Fellow at Ysios Capital and contributed to a clinical research study.
Asabys partner Montse Vendrell serves on the boards of Ona Therapeutics, InBrain Neuroelectronics, Peptomyc and Accure, and is an independent director at Oryzon genomics. She was a partner at Aliath Bioventures and Alta Life Sciences.
Pilar Almajano joined Asabys in 2025 as financial controller, responsible for financial operations, accounting and investor reporting. She previously managed audit clients at EY Audit Services in Barcelona across sectors including pharmaceuticals, retail and pool & wellness.
The roster lists co-founders and managing partners Josep Ll. Sanfeliu and Clara Campàs; partners Sylvain Sachot, Guillem Masferrer, Montse Vendrell and Jose María Fernández; and other operating, finance and investment staff.
The page lists the contact address Via Laietana, 26, 5th. floor, 08003 Barcelona, Spain, and the email info@asabys.com.
Asabys is an investment firm based in Barcelona that invests in healthcare and life-sciences innovation and works with its portfolio companies.